MedTrace Logo

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

NCT01055184 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2016-05-30

Study results available
· View outcomes & findings →

Summary

Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older. It may be that older people have had greater exposure to previous strains of H1N1 influenza, and this previous exposure protects them from infection. This study will examine how older people respond to a version of the H1N1 virus vaccine that includes a live, noninfectious version of the virus.

Conditions

  • 2009 H1N1 Influenza Virus

Interventions

BIOLOGICAL

2009 H1N1 Virus Vaccine

Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Rochester

    lead OTHER

Principal Investigators

  • John Treanor, MD · University of Rochester

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01055184 on ClinicalTrials.gov